183 related articles for article (PubMed ID: 37691865)
1. Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with
Nishio K; Sakai K; Nishio M; Seto T; Visseren-Grul C; Carlsen M; Matsui T; Enatsu S; Nakagawa K
Transl Lung Cancer Res; 2023 Aug; 12(8):1702-1716. PubMed ID: 37691865
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.
Garon EB; Reck M; Nishio K; Heymach JV; Nishio M; Novello S; Paz-Ares L; Popat S; Aix SP; Graham H; Butts BD; Visseren-Grul C; Nakagawa K;
ESMO Open; 2023 Aug; 8(4):101580. PubMed ID: 37390764
[TBL] [Abstract][Full Text] [Related]
3. Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic
Nishio K; Seto T; Nishio M; Reck M; Garon EB; Sakai K; Goto K; Kato T; Nakanishi Y; Takahashi T; Yamamoto N; Kiura K; Ohe Y; Tamura T; Visseren-Grul C; Frimodt-Moller B; Hozak RR; Wijayawardana SR; Zimmermann A; Homma G; Enatsu S; Nakagawa K
JTO Clin Res Rep; 2021 Jun; 2(6):100171. PubMed ID: 34590023
[TBL] [Abstract][Full Text] [Related]
4. Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
Nishio M; Seto T; Reck M; Garon EB; Chiu CH; Yoh K; Imamura F; Park K; Shih JY; Visseren-Grul C; Frimodt-Moller B; Zimmermann A; Homma G; Enatsu S; Nakagawa K;
Cancer Sci; 2020 Dec; 111(12):4510-4525. PubMed ID: 32954593
[TBL] [Abstract][Full Text] [Related]
5. RELAY, Erlotinib Plus Ramucirumab in Untreated,
Nishino K; Shih JY; Nakagawa K; Reck M; Garon EB; Carlsen M; Matsui T; Visseren-Grul C; Nadal E
JTO Clin Res Rep; 2024 Feb; 5(2):100624. PubMed ID: 38304857
[TBL] [Abstract][Full Text] [Related]
6. RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer.
Nakagawa K; Nadal E; Garon EB; Nishio M; Seto T; Yamamoto N; Park K; Shih JY; Paz-Ares L; Frimodt-Moller B; Zimmermann AH; Wijayawardana S; Visseren-Grul C; Reck M
Clin Cancer Res; 2021 Oct; 27(19):5258-5271. PubMed ID: 34301751
[TBL] [Abstract][Full Text] [Related]
7. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome.
Nishio M; Paz-Ares L; Reck M; Nakagawa K; Garon EB; Popat S; Ceccarelli M; Graham HT; Visseren-Grul C; Novello S
Clin Lung Cancer; 2023 Jul; 24(5):415-428. PubMed ID: 37076395
[TBL] [Abstract][Full Text] [Related]
8. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe/United States subset analysis.
Ponce Aix S; Novello S; Garon EB; Nakagawa K; Nadal E; Moro-Sibilot D; Alonso Garcia M; Fabre E; Frimodt-Moller B; Zimmermann AH; Visseren-Grul CM; Reck M;
Cancer Treat Res Commun; 2021; 27():100378. PubMed ID: 33905962
[TBL] [Abstract][Full Text] [Related]
9. RELAY, Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients with Untreated, Epidermal Growth Factor Receptor Mutation-Positive, Metastatic Non-Small-Cell Lung Cancer: Safety Profile and Manageability.
Nadal E; Horinouchi H; Shih JY; Nakagawa K; Reck M; Garon EB; Wei YF; Kollmeier J; Frimodt-Moller B; Barrett E; Lipkovich O; Visseren-Grul C; Novello S
Drug Saf; 2022 Jan; 45(1):45-64. PubMed ID: 34928484
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.
Chiu CH; Lin MC; Wei YF; Chang GC; Su WC; Hsia TC; Su J; Wang AK; Jen MH; Puri T; Shih JY
Target Oncol; 2023 Jul; 18(4):505-515. PubMed ID: 37329423
[TBL] [Abstract][Full Text] [Related]
11. RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure-response relationship.
Nakagawa K; Garon EB; Gao L; Callies S; Zimmermann A; Walgren R; Visseren-Grul C; Reck M
Cancer Chemother Pharmacol; 2022 Aug; 90(2):137-148. PubMed ID: 35841410
[TBL] [Abstract][Full Text] [Related]
12. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
[TBL] [Abstract][Full Text] [Related]
13. RELAY+: Exploratory Study of Ramucirumab Plus Gefitinib in Untreated Patients With
Nishio M; Nishio K; Reck M; Garon EB; Imamura F; Kawaguchi T; Yamaguchi H; Ikeda S; Hirano K; Visseren-Grul C; Ceccarelli M; Wijayawardana SR; Zimmermann A; Matsui T; Enatsu S; Nakagawa K
JTO Clin Res Rep; 2022 Apr; 3(4):100303. PubMed ID: 35369607
[TBL] [Abstract][Full Text] [Related]
14. Randomized, Double-Blind Phase Ib/III Study of Erlotinib With Ramucirumab or Placebo in Previously Untreated EGFR-Mutant Metastatic Non-Small-Cell Lung Cancer (RELAY): Phase Ib Results.
Reck M; Garon EB; Paz-Ares L; Ponce S; Jaime JC; Juan O; Nadal E; Kiura K; Widau RC; He S; Dalal R; Lee P; Nakagawa K
Clin Lung Cancer; 2018 May; 19(3):213-220.e4. PubMed ID: 29317191
[TBL] [Abstract][Full Text] [Related]
15. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
16. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
[TBL] [Abstract][Full Text] [Related]
17. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
18. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
[TBL] [Abstract][Full Text] [Related]
19. Total and mutated EGFR quantification in cell-free DNA from non-small cell lung cancer patients detects tumor heterogeneity and presents prognostic value.
Alegre E; Fusco JP; Restituto P; Salas-Benito D; Rodríguez-Ruiz ME; Andueza MP; Pajares MJ; Patiño-García A; Pio R; Lozano MD; Gúrpide A; Lopez-Picazo JM; Gil-Bazo I; Perez-Gracia JL; Gonzalez A
Tumour Biol; 2016 Oct; 37(10):13687-13694. PubMed ID: 27473086
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the efficacy and safety of first-line treatments for of advanced EGFR mutation-positive non-small-cell lung cancer in Asian populations: a systematic review and network meta-analysis.
Chen W; Miao J; Wang Y; Xing W; Xu X; Wu R
Front Pharmacol; 2023; 14():1212313. PubMed ID: 37484016
[No Abstract] [Full Text] [Related]
[Next] [New Search]